Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival.
Shapiro RM, Kim HT, Dulery R, Liney D, Garrity HM, Panaro KM, Au C, Gervais C, Little JS, Ho VT, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Romee R, Wu CJ, Ritz J, Soiffer RJ, Nikiforow S. Shapiro RM, et al. Among authors: ho vt. Blood Adv. 2024 May 15:bloodadvances.2023012418. doi: 10.1182/bloodadvances.2023012418. Online ahead of print. Blood Adv. 2024. PMID: 38748871
Comparison of older related vs younger unrelated donors for old recipients of allogeneic hematopoietic cell transplantation with AML or MDS- a large single center analysis.
Kim HT, Ho VT, Nikiforow S, Cutler C, Koreth J, Shapiro RM, Gooptu M, Romee R, Wu CJ, Antin JH, Ritz J, Soiffer RJ. Kim HT, et al. Among authors: ho vt. Transplant Cell Ther. 2024 May 3:S2666-6367(24)00375-0. doi: 10.1016/j.jtct.2024.05.001. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38703824
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Contreras ME, Fell G, Letai A, Ritz J, Lindsley RC, Soiffer RJ, Antin JH. Garcia JS, et al. Among authors: ho vt. Blood Adv. 2024 Feb 27;8(4):978-990. doi: 10.1182/bloodadvances.2023012120. Blood Adv. 2024. PMID: 38197938 Free PMC article.
Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions.
Bracken SJ, Suthers AN, DiCioccio RA, Su H, Anand S, Poe JC, Jia W, Visentin J, Basher F, Jordan CZ, McManigle WC, Li Z, Hakim FT, Pavletic SZ, Bhuiya NS, Ho VT, Horwitz ME, Chao NJ, Sarantopoulos S. Bracken SJ, et al. Among authors: ho vt. Blood Adv. 2024 Feb 13;8(3):667-680. doi: 10.1182/bloodadvances.2023010362. Blood Adv. 2024. PMID: 38113462 Free PMC article.
Dual anticancer and antibacterial activity of fluorescent naphthoimidazolium salts.
Tran DN, Hoang TTH, Nandanwar S, Ho VTTX, Pham VT, Vu HD, Nguyen XH, Nguyen HT, Nguyen TV, Nguyen TKV, Tran DL, Park M, Lee S, Pham TC. Tran DN, et al. Among authors: ho vttx. RSC Adv. 2023 Dec 14;13(51):36430-36438. doi: 10.1039/d3ra06555c. eCollection 2023 Dec 8. RSC Adv. 2023. PMID: 38099251 Free PMC article.
Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft.
Little JS, Duléry R, Shapiro RM, Aleissa MM, Prockop SE, Koreth J, Ritz J, Antin JH, Cutler C, Nikiforow S, Romee R, Issa NC, Ho VT, Baden LR, Soiffer RJ, Gooptu M. Little JS, et al. Among authors: ho vt. Transplant Cell Ther. 2024 Feb;30(2):233.e1-233.e14. doi: 10.1016/j.jtct.2023.11.015. Epub 2023 Nov 18. Transplant Cell Ther. 2024. PMID: 37984797
305 results